SynthesisAmerican journal of ophthalmology2014
Lipids, lipid genes, and incident age-related macular degeneration: the three continent age-related macular degeneration consortium.
Synthesis in American journal of ophthalmology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed, 5 syntheses or guidelines pooled it, 98 citations in OpenAlex.
- [Risk factors for age-related macular degeneration : Lessons learned from current data].Die Ophthalmologie · 2025Pooled it
- Risk factors for wet macular degeneration: a systematic review, with novel insights from the Scottish Heart Health Extended Cohort.BMC ophthalmology · 2025Pooled it
- HDL-cholesterol levels and risk of age-related macular degeneration: a multiethnic genetic study using Mendelian randomization.International journal of epidemiology · 2017Pooled it
- The Association between the Lipids Levels in Blood and Risk of Age-Related Macular Degeneration.Nutrients · 2016Pooled it
- The association between statin use and risk of age-related macular degeneration.Scientific reports · 2015Pooled it
- Risk factors for age-related macular degeneration.Die Ophthalmologie · 2026Review
- CETP Renaissance with Obicetrapib.Current atherosclerosis reports · 2026Review
- Trends, hotspots, and future directions of inflammation in age-related macular degeneration: A 20-year bibliometric study.Medicine · 2026Article
- Atorvastatin Alleviates Age-Related Macular Degeneration via AIM2-Regulated Pyroptosis.Inflammation · 2025Article
- High-Density Lipoproteins Associated with Age-Related Macular Degeneration in the All of Us Research Program.Ophthalmology · 2025Article
- Long-term macular atrophy growth in neovascular age-related macular degeneration: influential factors and role of genetic variants.Eye (London, England) · 2025Article
- Role of LIPIN 1 in regulating metabolic homeostasis in the retinal pigment epithelium.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2024Article
- Unveiling Statins and Genetics in Age-Related Macular Degeneration: The Coimbra Eye Study-Report 9.Investigative ophthalmology & visual science · 2024Article
- Workshop report - interdisciplinary metabolomic epidemiology: the pathway to clinical translation.Metabolomics : Official journal of the Metabolomic Society · 2024Article
- Bottlenecks in the Investigation of Retinal Sterol Homeostasis.Biomolecules · 2024Review
- Coronary artery disease, its associations with ocular, genetic and blood lipid parameters.Eye (London, England) · 2024Article
- Multi-Wavelength Photobiomodulation Ameliorates Sodium Iodate-Induced Age-Related Macular Degeneration in Rats.International journal of molecular sciences · 2023Article
- The Role of Inflammation in Age-Related Macular Degeneration-Therapeutic Landscapes in Geographic Atrophy.Cells · 2023Review
- Analysis of Systemic and Serum Risk Factors in Patients with Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy.Ophthalmology and therapy · 2023Article
- Article
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 7 institutions in 4 countries.
Funding
Abstract
purposeTo describe associations of serum lipid levels and lipid pathway genes to the incidence of age-related macular degeneration (AMD).
designMeta-analysis.
methodssetting: Three population-based cohorts. population: A total of 6950 participants from the Beaver Dam Eye Study (BDES), Blue Mountains Eye Study (BMES), and Rotterdam Study (RS). observation procedures: Participants were followed over 20 years and examined at 5-year intervals. Hazard ratios associated with lipid levels per standard deviation above the mean or associated with each additional risk allele for each lipid pathway gene were calculated using random-effects inverse-weighted meta-analysis models, adjusting for known AMD risk factors. main outcome measures: Incidence of AMD.
resultsThe average 5-year incidences of early AMD were 8.1%, 15.1%, and 13.0% in the BDES, BMES, and RS, respectively. Substantial heterogeneity in the effect of cholesterol and lipid pathway genes on the incidence and progression of AMD was evident when the data from the 3 studies were combined in meta-analysis. After correction for multiple comparisons, we did not find a statistically significant association between any of the cholesterol measures, statin use, or serum lipid genes and any of the AMD outcomes in the meta-analysis.
conclusionIn a meta-analysis, there were no associations of cholesterol measures, history of statin use, or lipid pathway genes to the incidence and progression of AMD. These findings add to inconsistencies in earlier reports from our studies and others showing weak associations, no associations, or inverse associations of high-density lipoprotein cholesterol and total cholesterol with AMD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.